NCT00275275View on ClinicalTrials.gov

Pramipexole Conversion to Ropinirole Controlled Release (CR)

PHASE3CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Parkinson Disease
Interventions
DRUG

Requip PR

Requip 24-Hour once a day for one month

DRUG

Mirapex

All subjects started the study on Mirapex. They were all then switched to Requip PR based on a conversion factor of 1:3, 1:4 or 1:5.

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Rajesh Pahwa, MD

OTHER